- Home
- RENEU vs TGTX Comparison
RENEU vs TGTX Comparison
Compare RENEU & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENEU
- TGTX
- Stock Information
- Founded
- RENEU N/A
- TGTX 1993
- Country
- RENEU
- TGTX United States
- Employees
- RENEU 2
- TGTX N/A
- Industry
- RENEU
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RENEU
- TGTX Health Care
- Exchange
- RENEU NYSE
- TGTX Nasdaq
- Market Cap
- RENEU N/A
- TGTX 5.4B
- IPO Year
- RENEU N/A
- TGTX 1995
- Fundamental
- Price
- RENEU $11.63
- TGTX $31.06
- Analyst Decision
- RENEU
- TGTX Strong Buy
- Analyst Count
- RENEU 0
- TGTX 6
- Target Price
- RENEU N/A
- TGTX $40.67
- AVG Volume (30 Days)
- RENEU N/A
- TGTX 1.9M
- Earning Date
- RENEU N/A
- TGTX 02-26-2025
- Dividend Yield
- RENEU N/A
- TGTX N/A
- EPS Growth
- RENEU N/A
- TGTX N/A
- EPS
- RENEU N/A
- TGTX N/A
- Revenue
- RENEU N/A
- TGTX $264,790,000.00
- Revenue This Year
- RENEU N/A
- TGTX $44.11
- Revenue Next Year
- RENEU N/A
- TGTX $63.92
- P/E Ratio
- RENEU N/A
- TGTX N/A
- Revenue Growth
- RENEU N/A
- TGTX 39.53
- 52 Week Low
- RENEU N/A
- TGTX $12.84
- 52 Week High
- RENEU N/A
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- RENEU 99.15
- TGTX 47.35
- Support Level
- RENEU $11.37
- TGTX $29.90
- Resistance Level
- RENEU $11.80
- TGTX $33.55
- Average True Range (ATR)
- RENEU 0.00
- TGTX 1.78
- MACD
- RENEU -0.01
- TGTX -0.37
- Stochastic Oscillator
- RENEU 0.00
- TGTX 22.61
About RENEU CARTESIAN GROWTH CORPORATION II UNIT COM 1 CL A & 1/3 WT EXP(12/07/2028)
Cartesian Growth Corp II is a blank check company.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.